Floatz logo

Therapeutic Asset Ratings

6,299 results matching 1 filter

91,565 assets7,904 sponsors3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Olaparib
Diffuse Intrinsic Pontine Glioma
Fundación de investigación HMP1/2CC (45)
Olaparib
Paraganglioma
Fundación de investigación HMP1/2CC (45)
Olaparib
Pheochromocytoma
Fundación de investigación HMP1/2CC (45)
Olaparib
Synovial Sarcoma
Fundación de investigación HMP1/2CC (45)
Olomorasib
Endometrial Cancer
Eli Lilly and CompanyP1/2CC (45)
Olomorasib
Pancreatic Neoplasm
Eli Lilly and CompanyP1/2CC (45)
Olverembatinib
Myeloid Neoplasm
Ascentage Pharma Group Inc.P1/2CC (45)
Onivyde
Refractory Malignant Neoplasm
St. Jude Children's Research HospitalP1/2CC (45)
ont01
Pancreatic Ductal Adenocarcinoma
Washington University School of MedicineP1/2CC (45)
Opc-415
Plasma Cell Myeloma
Otsuka Pharmaceutical Co., Ltd.P1/2CC (45)
or502
Neoplasm
OncoResponse, Inc.P1/2CC (45)
Orca-Q
Acute Myeloid Leukemia
University of FloridaP1/2CC (45)
Ose-279
Non-Small Cell Lung Carcinoma
OSE ImmunotherapeuticsP1/2CC (45)
Osimertinib
Mesothelioma
Ikena OncologyP1/2CC (45)
Palacaparib
Squamous Cell Lung Carcinoma
AstraZenecaP1/2CC (45)
Palbociclib
Fallopian Tube Cancer
Avenzo Therapeutics, Inc.P1/2CC (45)
Panitumumab
Metastatic Malignant Neoplasm In The Brain
Institut de Recherches Internationales ServierP1/2CC (45)
Panitumumab
Digestive System Cancer
Anup KasiP1/2CC (45)
Panitumumab
Histiocytosis
Institut de Recherches Internationales ServierP1/2CC (45)
Part A: Ose-279
Non-Small Cell Lung Carcinoma
OSE ImmunotherapeuticsP1/2CC (45)
Pasifolate Exatecan
Endometrium Adenocarcinoma
Elucida OncologyP1/2CC (45)
Pasifolate Exatecan
Uterine Carcinosarcoma
Elucida OncologyP1/2CC (45)
Pasifolate Exatecan
Endometrial Clear Cell Adenocarcinoma
Elucida OncologyP1/2CC (45)
Pasifolate Exatecan
Endometrioid Adenocarcinoma
Elucida OncologyP1/2CC (45)
Pasifolate Exatecan
Endometrioid Tumor
Elucida OncologyP1/2CC (45)
Showing 3726 to 3750 of 6,299 assets
PreviousPage 150 of 252Next